Search results

Disappointing to see this. We've discussed Neuroversion in a few places on the forum, e.g. here Stellate ganglion block reduces symptoms of Long COVID: A case series (2021) Liu et al That company is certainly good at marketing, they were all over the IACFSME conference. I don't think there is...

Great analyses. I think the short term nature of the subjective effect is a key point. We have discussed the asthma trial and the Mendus ME/CFS trial of MitoQ with the blinded and open treatment arms that show how easy it is to generate a positive short term result when outcomes are subjective...

Something that could help is the National Ethics Advisory Committee's 'Ethical guidance for a Pandemic'. NEAC is currently calling for submissions on the draft. The deadline keeps shifting further out each time I look, it's now 1 November 2022. There is mention of Long Covid, but much more...

This tells us that people who have had Covid-19 one to 6 months ago are different to healthy controls (I think the healthy controls had never had Covid, as the blood was taken from a blood bank) and also are different to people hospitalised with acute Covid-19. I don't think it tells us that...

Link to an article about the study

If you had one treatment trial and you knew that 20% of the participants didn't have the disease you are interested in, but 80% did, and there was a 70% rate of substantial improvement, then the trial would be useful, all other things being done properly. I think it would be methodologically...

Thanks for that detailed report @ME/CFS Skeptic. So the analysis IQWIG did seems ok - I mean we could argue over 95% with PEM versus 80% with PEM, but the 80% seems defendable when there is no better information to go on, so long as the uncertainty it creates (not to mention the issues with...

There's a good summary of previous epidemiological studies in the introduction with commentary on the problems in these types of studies. Unfortunately, this one also has a problem with selection bias, due to a low response rate: People with ongoing symptoms will surely be a lot more likely to...

When you've got a hammer, the world's a nail. And, if it isn't a nail, then bash it until it says it's a nail.

Great to hear that there is finally some decent progress.

Yes, I agree that the literature is questionable. Often rates of depression on ME/CFS are not set in the context of rates in the general population - when prevailing rates are compared, the ME/CFS ones are often unremarkable. We also know that the tools for measuring depression are skewed by...

:rofl: I thought perhaps Dolphin was cleverly making a snide but subtle commentary about the nature of this paper. But no, that is really how the journal Psychoanalysis, Culture & Society should be cited. I think the abbreviation says most of what needs to be said about this paper.

The reaction occurred 72 hours after the vaccination. It's hard to know in this case if the swelling around the throat would have happened without the vaccination, given the past episodes of upper limb swelling. More likely, perhaps it would have been triggered by any immunological challenge -...

I have had problems with clothes moths since developing ME/CFS too. In my case, the scientific explanation might just be that certain segments of my wardrobe (e.g. fine woollen knits and suits) weren't getting to see the light of day anymore (or the dry cleaners or the washing machine) leaving...

A nice read

Looks very much like the latter then. I don't think pacing is a therapy. And, wow, that's quite the twisting of the outcomes. A 127,047 UK pounds cost for a benefit from pacing. Given pacing is just finding ways to cope with a reduced capacity for activity, nearly every participant in PACE...

I've got to say, it's disappointing to have this analysis in Virology blog. There's no context, no discussion of the issues with cortisol testing (a single moment versus daily; the interplay between timing of collection and waking time and lifestyle in general; findings in ME/CFS that...

Image by Hilda from Hilda's blog. "Zombie" seems like a perfect term for the existing Cochrane Exercise Therapy for CFS review - it's long dead, but it continues to walk mindlessly, causing harm. So, Hilda is saying that Cochrane reviews should be regarded as living reviews, subject to...

Maybe, "it's dreadfully sad that this person is sick, hopefully he will recover ok soon, but ... well, it's a great opportunity to look at his cells post-LC onset."? I presume that they will do that.